Founded in 2004, Pharmaron is a cutting-edge, fully integrated pharmaceutical R&D service platform supporting the life science industry. The company has invested in its people and facilities and established its comprehensive service offerings throughout the pharmaceutical R&D lifecycle. With operations in China, the US and the UK staffed by more than 11,000 employees, Pharmaron has an excellent track record in delivering end-to-end R&D solutions to its partners globally and enabling them to accelerate their novel drug discovery and development process.
Pharmaron is a contract research organization (CRO).
* Synthetic, medicinal and analytical chemistry services
* Biology services
* DMPK services
* Pharmacology services
* Drug safety assessment services
* Radiochemistry and isotopically labelled metabolism services
* Chemical & pharmaceutical development services
* Clinical development services
CRO - Contract Research Organization
Discovery Process Chemistry
Radiolabelled Chemical Synthesis
in vitro Biology
in vitro Screening
in vivo Pharmacology
Animal Disease Models
ex vivo Pharmacology
in vitro ADME
in vivo PK
Drug Product Manufacturing
14C / Carbon-14 Radiosynthesis
3H / Tritium Radiosynthesis
Microdosing Phase 0
Altogen Labs is a biology CRO company providing GLP preclinical research services, tox studies for IND applications, RNAi and gene silencing services, xenograft testing services (100+ tumorigenic cell lines), in vivo siRNA delivery and biodistribution, development of stable cell lines, and many more.
Altogen Labs is a GLP compliant laboratory that provides preclinical research and biotechnology contract research services (CRO) to pharma, biotechnology companies, universities, and cancer research centers worldwide. Our services include pharmacology and toxicology assays (IC50), cell banking, generation of stable cell lines, RNAi gene silencing and other in vitro services. Altogen Labs provides following in vivo services for efficacy studies in the drug discovery phase: rodent xenograft models, teratoma formation and analysis services, cancer disease animal models, in vivo siRNA delivery and tissue targeting, pharmacokinetics (PK) and pharmacodynamics (PD) services, immune response and biomarker analysis.
Altogen Labs recently developed an `active bioremediation` process based on an approach using the most potent oil-degrading bacteria found at multiple oil spill sites in Texas. This technology allows remediation of large amounts of hydrocarbon-contaminated liquids or soil. The genomes of both microorganisms were recently sequenced, which revealed that both strains were previously unreported in the literature. Altogen Labs filed bioremeddiation patent application in 6/2012.
Applied StemCell Inc. (ASC) is a fast growing biotechnology company headquartered in Milpitas, California. Our goal is to advance gene-editing and stem cell innovation for biomedical research and the biotechnology industry. After years of research and development, ASC is proud to offer an optimized series of tools for basic research study, drug discovery, bio-processing, bio-production and preclinical applications.
We are currently focusing on three areas: (1) cell line generation for bio-production and bioassays (2) patient-relevant cell models for personalized medicine and (3) physiologically predictive animal models of human diseases. We are striving to improve and expand our technologies and product lines to meet the increasing requirements of the biomedical community.
• Stem Cells & Cell Line Models
• Mouse Model Generation
• AAV Potency Assay
• Antibody Discovery & Screening
• Regenerative Medicine
• Pre-IND Filing Consultation
Using our TARGATT™ technology, a gene-of-interest can be specifically inserted at a well-characterized, transcriptionally active locus in the genome with guaranteed transgene expression. This site-specific Knock-in technology has been first established in mouse models, and we have successfully applied it to human cell lines. We are moving forward to various projects that will combine the CRISPR/Cas9 technology and TARGATT™ for highly specified transgene expression.
For patent licensing, business development, and investment inquiries, please contact us at email@example.com.
CellMosaic®, Inc. is an innovator and leader in bioconjugation and crosslinking technologies. The company was established in 2008 by Dr. Huang, a technological entrepreneur with profound interest and experience in the conjugation field. Since 2008, CellMosaic® has spent a lot of research effort on developing advanced conjugation processes that involve controlled, site-specific, or single labeling methods. These processes can generate single ratio conjugates with greater than 90% purity. We have built a successful custom conjugation service business based on these processes and delivered more than 150 projects and 100 unique conjugates (as of Apr. 2017) for our customers covering a variety of compounds, including proteins, antibodies, peptides, oligos, enzymes, and chemotherapeutic agents. Recently, CellMosaic started to commercialize personalized™ conjugation kits (PerKit™) based on these conjugation processes. Customers can use these kits in house to prepare conjugates with similar high quality as we do at CellMosaic.
Over the years, CellMosaic® has also pioneered the concept of utilizing sugar alcohol (SA) monomers to chemically assemble a new type of crosslinking reagents and polymer carriers, called AqueaTether™ (AqT™), for conjugation and drug delivery. Several other key technologies have also been developed at CellMosaic®, including oxLink™ and sxLink™ technologies for studying protein–protein interactions, and NeIon™ technologies for detecting and quantitating trace amounts of analytes of interest by Mass Spectrometry. Currently, we are developing products using these technologies for R&D usage.
One of the main goals of developing AqT™ linkers and polymers is for drug conjugation and delivery. Please visit www.aqttherapeutics.com to learn more about these applications. Customers who wish to develop their own proprietary therapeutics based on AqT linkers and polymers are encouraged to contact us for how to access these technologies.
At Qoolabs, we use the QMab™ (Quick Monoclonal Antibody from Blood) platform to generate novel antibodies. Rabbit monoclonal antibodies are cloned from blood in three weeks when immunized rabbits are ready, with no need of killing animals. Antibodies can be cloned from blood collected at multiple time points and selected with functional assays. To learn more about the QMab™ technology, please email your inquiry to firstname.lastname@example.org.
We are highly skilled in developing lateral flow rapid tests and ELISAs. Our featured products are His-tag and Fc-fusion protein rapid tests, biotin quantitation kits, CMV antibody rapid tests, and Hepatitis B virus core antigen ELISA kits. 37ExpressVue® Rapid Tests detect recombinant fusion protein or epitope tagged proteins of interest. KnowNow!® Rapid Tests detect native proteins directly from biological samples and culture media. QNow® Quantitative Rapid Tests quantitate target molecules. QTiter™ ELISA kits are highly sensitive and specific. Visit our website www.qoolabs.com for product info, or contact us at “email@example.com” for custom immunoassay development.